Effect of Dapagliflozin on IAH in T1DM

Exclusion Criteria

• •Treatment with SGLT-2 inhibitors
• •Known intolerance to SGLT-2 inhibitors
• •Treatment with loop diuretics or other anti-hypertensive agents
• •Treatment with glucose-modifying (other than insulin) or immune-modifying agents (e.g. prednisolon)
• •Treatment with pioglitazone
• •Use of statins
• •A history of cardiovascular disease (e.g. myocardial infarction, stroke, heart failure) or hypotension
• •A history of galactose-intolerance, lactase deficiency, glucose-galactose malabsorption
• •History of diabetic ketoacidosis requiring medical intervention within 1 month before screening
• •Admission to the hospital for hyperglycemia or hypoglycemia within 1 month before screening
• •Frequent episodes of severe hypoglycemia within 1 month before screening
• •Laser coagulation for proliferative retinopathy (past 6 months)
• •Proliferative retinopathy
• •Diabetic nephropathy as reflected by an albumin-creatinin ratio ˃ 30 mmol/mg or an estimated glomerular filtration rate (by MDRD) ˂60ml/min/1.73m2
• •History of pancreatitis (acute or chronic) or pancreatic cancer
• •Use of premixed insulin or of long-acting insulin alone
• •Total daily insulin dose requirements \<20 units unless on pump treatment
• •Pregnancy or unwillingness to undertake measures for birth control